WinstonWınston
Back
Escalon Medical logo

Escalon Medical

ESMC
38
Medical - Devices · Healthcare
Price
$0.18
+0.00 (+0.00%)
Market Cap
$1.3M
Winston Score
38
Winston is serious
Below-average fundamentals — multiple weak pillars.
Data as of Aug 23, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Weak
Growth
Mixed
Cash Flow
Exceptional
Stability
Good
Valuation
Good

Share count rising — dilution

+92.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.4M (2021) → 14.3M (2025)

Winston Score History

The full picture

Escalon Medical Corp. makes medical devices and supplies used by eye doctors and hospitals. Its main products include equipment for eye surgery, ultrasound imaging tools for the eye, and related consumable supplies. The company sells primarily to ophthalmologists, eye clinics, and surgical centers in the United States and some international markets.

Escalon earns revenue by selling its devices outright and through ongoing sales of disposable supplies that customers need to keep using the equipment. It is a small company, with a market cap under $100 million, and competes against much larger medical device makers like Alcon and Bausch + Lomb. The company currently operates at a loss, as shown by its negative operating and return margins, which means its costs exceed what it brings in — the main risk is whether it can grow sales fast enough to reach consistent profitability in a market dominated by well-funded competitors.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-24.9% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+774.3% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$753M/ year

Rising (+109337% vs prior year)

>1,000% of revenue

347.3x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

1.9%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$3.3B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Escalon Medical is putting 6252% of revenue into R&D and that number is rising. That's 347.3x the sector average. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
36.3%
Modest — 36.3% gross margin
Profit after running costs
Operating Margin
-16.1%
Losing money on operations — -16.1%
Return on the money invested
ROCE
-20.9%
Weak — -20.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-11.6%
Shrinking sales (-11.6% YoY)
Profit growth
EPS YoY
+114.7%
Earnings growing fast (+114.7% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
15153%
Turns 15153% of profit into real cash
Spare cash per sale
FCF Margin
2451.2%
Converts sales into free cash efficiently (2451.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.03
Conservative — low debt load (0.03)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
1.7x
Attractive valuation — P/E 1.7

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial